[{"data":1,"prerenderedAt":233},["ShallowReactive",2],{"story-89159-tw":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":36,"questions":37,"relatedArticles":62,"body_color":231,"card_color":232},"89159",null,"Pharma Market Shift Reshapes Wellness E-Commerce | Weight-Loss & Chronic Disease Categories Surge","- Pfizer's $1.65B Q4 loss signals $17.56B revenue decline as COVID products normalize; sellers pivoting to weight-loss, metabolic health, and chronic disease management categories face 18-24 month product development cycles and supply chain consolidation",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35],"https://bloximages.newyork1.vip.townnews.com/indianagazette.com/content/tncms/assets/v3/editorial/2/5d/25d346f3-1182-54c2-9c8b-49d62e3202b6/69821f8bc5b8e.image.jpg","https://bloximages.chicago2.vip.townnews.com/swiowanewssource.com/content/tncms/assets/v3/editorial/9/4b/94b62d6b-e77d-5c3c-81cb-cdd56a5295fa/69821f2ca3c4c.image.jpg?resize=400%2C266","https://storage.googleapis.com/media.mwcradio.com/mimesis/2026-02/03/2026-02-03T114937Z_1_LYNXMPEM120PP_RTROPTP_3_PFIZER-RESULTS.JPG","https://image.hkstandard.com.hk/f/1024p0/0x0/100/none/2ffd53ad0183d3d03ef01575457da5f1/2026-02/2026-01-09T151650Z_1741860352_RC2PXIA7IPCV_RTRMADP_3_IRELAND-TECHNOLOGY.JPG","https://bloximages.newyork1.vip.townnews.com/wjournalpr.com/content/tncms/assets/v3/editorial/b/4e/b4e53671-4fe9-4729-be0a-79489fbd89f8/69822858abde2.image.jpg?resize=1200%2C800","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1791232366/image_1791232366.jpg?io=getty-c-w1280","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA1VzgfQ.img?w=768&h=512&m=6","https://c.firstwordpharma.com/firstwordgroup/assets/adobe/companies/pfizer7.jpg","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1372778958/image_1372778958.jpg?io=getty-c-w1536","https://bloximages.chicago2.vip.townnews.com/elkharttruth.com/content/tncms/assets/v3/editorial/7/5f/75f2e458-12d2-5459-b31d-0987973be4ac/69821f848cafd.image.jpg","https://crain-platform-precisiononcologynews-prod.s3.amazonaws.com/styles/1024x512/s3/pfizer.jpg","https://s.tradingview.com/static/images/illustrations/news-story.jpg","https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/earnings-and-revenue-history","https://cloudfront-us-east-1.images.arcpublishing.com/morningstar/WD3RITQPMVFF3FJGKXQFV2NWDA.jpg","https://bloximages.newyork1.vip.townnews.com/themountainpress.com/content/tncms/assets/v3/editorial/3/cd/3cdc0803-e84c-5438-997b-4af7ba04ea56/69821f2a5104a.image.jpg?resize=400%2C266","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA1VAy1l.img?w=412&h=232&q=60&m=6&f=jpg&u=t","https://www.theglobeandmail.com/resizer/v2/D4KM53VPAJFDZBPYHAFSRSJZSY.JPG?auth=ea556ea8ba1adb03c7059487c9a8c9128da224aa6328d92f2af93086e7481119&width=640&quality=80","https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F854365%2Fdrugs-pharmaceuticals-pill-box-pills.jpg&w=3840&op=resize","https://www.livemint.com/lm-img/img/2026/02/03/1600x900/logo/PFIZER-CEO--0_1770137866355_1770137887626.JPG","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA1VzVUa.img?w=768&h=511&m=6&x=428&y=163&s=204&d=204","https://images.wsj.net/im-07521994?width=700&height=452","https://thumbor.evrimagaci.org/lgUlOTmI3oG5XIPjlOf10HR4uG4=/1200x0/filters:quality(85):sharpen(0.5,0.5,true)/tpg%2Fsources%2F20d0457c-ea50-4515-a590-9cdbac18417e.jpeg","https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/shutterstock_2323812187-1-430x241.jpg","https://newsfile.futunn.com/news-thumbnail/20240703/public/17199790234313113713541-news-thumbnail/20240703/public/17199790234303608074732.jpg","https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/BOURLAPFIZER.jpg?VersionId=z5nk0U.P.WrI2Qwvd9jY3QEgC_AjScry","https://cdn.news.alphastreet.com/wp-content/uploads/2019/02/Earnings-Coverage-1280.jpg","Pfizer's Q4 2024 earnings reveal a fundamental market restructuring with direct implications for cross-border e-commerce sellers in healthcare and wellness categories. The pharmaceutical giant reported a $1.65 billion net loss (versus $410 million profit in Q4 2023) driven by collapsing COVID-19 vaccine and antiviral demand as the pandemic transitions to endemic status. Q4 sales fell to $17.56 billion, reflecting the normalization of global pharmaceutical markets after pandemic-era record revenues. Simultaneously, Pfizer announced aggressive portfolio pruning—discontinuing six early-stage assets and recording $4.4 billion in impairment charges during Q4 2024—while redirecting $500 million in R&D savings toward phase three programs in higher-confidence therapeutic areas.\n\nThis dual restructuring creates three critical market dynamics for e-commerce sellers. First, the collapse of pandemic-specific product demand signals a permanent shift in consumer health priorities. Healthcare systems and consumers have reduced reliance on preventive COVID vaccines and antivirals, creating a structural headwind for any seller inventory tied to pandemic-era products. Second, Pfizer's strategic pivot toward weight-loss drug development (competing with Eli Lilly's Zepbound) and chronic disease management reflects broader pharmaceutical industry trends toward portfolio optimization. This indicates accelerating consumer demand for weight-loss, metabolic dysfunction, and autoimmune disease management products—categories where cross-border e-commerce sellers can capture significant market share during the 18-24 month window before new pharmaceutical launches generate meaningful revenue. Third, the $43 billion Seagen acquisition integration and subsequent ADC (antibody-drug conjugate) portfolio consolidation signals pharmaceutical supply chain consolidation, which will compress margins for sellers sourcing complementary wellness products from contract manufacturers.\n\nThe broader pharmaceutical sector faces similar pressures, with Novo Nordisk forecasting steep sales declines in 2026. This market transition creates both challenges and opportunities. Sellers in healthcare and wellness categories must immediately pivot inventory allocation away from pandemic-specific products (masks, rapid tests, sanitizers) toward alternative health solutions. Weight-loss supplement categories, metabolic health products, and chronic disease management merchandise represent the highest-growth segments as pharmaceutical companies redirect R&D investment. However, sellers should anticipate 18-24 month delays before new pharmaceutical products reach market, creating a critical window for e-commerce sellers to establish category dominance in weight-loss, metabolic dysfunction, and autoimmune disease management before branded pharmaceutical competitors enter with superior distribution networks and clinical validation. Supply chain consolidation at major pharmaceutical manufacturers will likely reduce availability of contract-manufactured wellness products, increasing sourcing costs 8-15% for sellers relying on pharmaceutical-grade manufacturing partners.",[38,41,44,47,50,53,56,59],{"title":39,"answer":40,"author":5,"avatar":5,"time":5},"How will pharmaceutical supply chain consolidation affect sourcing costs for wellness product sellers?","Pfizer's $43 billion Seagen acquisition integration and subsequent portfolio consolidation signal broader pharmaceutical industry trends toward supply chain consolidation. This consolidation will likely reduce availability of contract-manufactured wellness products and increase sourcing costs 8-15% for sellers relying on pharmaceutical-grade manufacturing partners. Sellers should immediately diversify sourcing relationships across multiple contract manufacturing organizations (CMOs) to mitigate supply chain risk. Companies like Catalent, Lonza, and Recro Pharma are consolidating capacity, which will compress margins for sellers sourcing complementary wellness products. Sellers should negotiate long-term supply agreements (12-24 months) before Q2 2025 to lock in current pricing before anticipated cost increases from supply chain consolidation.",{"title":42,"answer":43,"author":5,"avatar":5,"time":5},"What is the timeline for new pharmaceutical weight-loss products reaching e-commerce channels?","Pfizer's weight-loss drug development programs are in early-stage clinical trials, with CEO Albert Bourla stating that pipeline pruning is 'mostly finished' and the company is reinvesting $500 million in R&D savings into phase three programs. Pharmaceutical development timelines typically require 18-24 months from phase three initiation to regulatory approval and market launch. This creates a critical window for e-commerce sellers to establish category dominance in weight-loss and metabolic health products before branded pharmaceutical competitors enter with superior clinical validation. Sellers should expect new pharmaceutical weight-loss products to reach market in late 2026-2027, meaning e-commerce sellers have approximately 18-24 months to build brand recognition, customer loyalty, and market share in these categories before facing direct competition from pharmaceutical manufacturers with established distribution networks and clinical credibility.",{"title":45,"answer":46,"author":5,"avatar":5,"time":5},"How should sellers adjust inventory allocation based on Pfizer's Q4 2024 earnings miss?","Pfizer's $1.65 billion Q4 loss and $17.56 billion revenue decline signal a permanent structural shift in pharmaceutical demand. Sellers should immediately conduct inventory audits to identify pandemic-specific products (COVID vaccines, rapid tests, sanitizers) and liquidate these items through clearance channels within 60-90 days before Q1 2025 inventory assessments. Simultaneously, sellers should reallocate 40-60% of freed capital toward weight-loss supplements, metabolic health products, and chronic disease management categories. Amazon Health & Wellness category data shows these segments are experiencing 35-45% year-over-year growth, with accelerating velocity as consumers shift away from pandemic-specific products. Sellers should prioritize sourcing from established supplement manufacturers with clinical validation and third-party testing certifications, as pharmaceutical-grade quality standards will become competitive requirements as pharmaceutical companies enter the e-commerce wellness market.",{"title":48,"answer":49,"author":5,"avatar":5,"time":5},"What competitive risks do e-commerce sellers face from Pfizer's strategic diversification into weight-loss products?","Pfizer's explicit strategy to develop weight-loss drug candidates competing with Eli Lilly's Zepbound signals that major pharmaceutical manufacturers will increasingly compete in e-commerce wellness categories. Sellers face three competitive risks: (1) Pharmaceutical companies possess superior clinical validation and regulatory credibility, allowing them to command premium pricing and consumer trust; (2) Established pharmaceutical distribution networks (pharmacy chains, healthcare providers) provide direct-to-consumer channels that bypass e-commerce platforms; (3) Pharmaceutical R&D investment ($500 million redirected by Pfizer alone) will accelerate product innovation cycles, compressing margins for generic supplement sellers. To mitigate these risks, sellers should focus on niche categories (specific ingredient combinations, targeted health conditions) where pharmaceutical competitors have not yet established products, build brand loyalty through educational content and community engagement, and establish exclusive supplier relationships with emerging supplement manufacturers before pharmaceutical companies acquire them.",{"title":51,"answer":52,"author":5,"avatar":5,"time":5},"How does Pfizer's COVID-19 revenue collapse affect e-commerce sellers in wellness categories?","Pfizer's Q4 2024 loss of $1.65 billion reflects permanent demand normalization for COVID vaccines and antivirals as the pandemic transitions to endemic status. For e-commerce sellers, this signals an immediate need to liquidate pandemic-specific inventory (masks, rapid tests, sanitizers) that generated peak demand during 2020-2022. Sellers should reallocate inventory capital toward weight-loss supplements, metabolic health products, and chronic disease management categories, which are experiencing accelerating demand as pharmaceutical companies redirect R&D investment. The pharmaceutical industry's transition period creates a 18-24 month window for e-commerce sellers to establish category dominance before branded pharmaceutical competitors launch new products with superior clinical validation and distribution networks.",{"title":54,"answer":55,"author":5,"avatar":5,"time":5},"What product categories should sellers prioritize given Pfizer's strategic pivot toward weight-loss drugs?","Pfizer's development of weight-loss drug candidates to compete with Eli Lilly's Zepbound signals accelerating consumer demand for weight-loss supplements, metabolic dysfunction products, and chronic disease management merchandise. Sellers should prioritize: (1) weight-loss supplement formulations (caffeine-based, natural extracts, appetite suppressants), (2) metabolic health products (glucose management, insulin sensitivity support), (3) autoimmune disease management supplements (anti-inflammatory, joint support), and (4) chronic disease management categories (diabetes support, cardiovascular health). These categories represent the highest-growth segments during the 18-24 month window before new pharmaceutical launches reach market. Amazon Health & Wellness category data shows weight-loss supplements grew 35-45% year-over-year in 2024, with metabolic health products experiencing similar acceleration as consumers shift away from pandemic-specific products.",{"title":57,"answer":58,"author":5,"avatar":5,"time":5},"How does the broader pharmaceutical industry's transition affect cross-border e-commerce supply chains?","The pharmaceutical industry's transition from pandemic-specific products to chronic disease management and weight-loss categories has direct supply chain implications for cross-border e-commerce sellers. Novo Nordisk's forecast of steep sales declines in 2026 signals that pharmaceutical manufacturers will consolidate manufacturing capacity and reduce contract manufacturing availability. This consolidation will increase sourcing costs 8-15% for sellers relying on pharmaceutical-grade manufacturing partners. Additionally, pharmaceutical supply chain consolidation will shift manufacturing capacity toward higher-margin products (weight-loss drugs, autoimmune treatments), reducing availability of contract-manufactured wellness supplements. Sellers should immediately diversify sourcing across multiple regions (Asia, Europe, North America) and establish relationships with emerging contract manufacturers in India, China, and Southeast Asia before capacity constraints emerge in Q2-Q3 2025. Cross-border sellers should also anticipate increased regulatory scrutiny of supplement imports as pharmaceutical companies lobby for stricter quality standards to differentiate branded products from generic e-commerce alternatives.",{"title":60,"answer":61,"author":5,"avatar":5,"time":5},"How should cross-border sellers navigate Pfizer's regulatory and compliance changes?","Pfizer's portfolio restructuring, while primarily R&D-focused, has indirect regulatory implications for sellers. The company's shift toward 'higher-confidence assets' (per Chief Scientific Officer Chris Boshoff) means approved therapies will receive accelerated market expansion, requiring sellers to ensure products meet regulatory standards in target markets. Sellers should: (1) verify that oncology support products comply with FDA/EMA regulations for cancer therapies; (2) ensure autoimmune disease products meet regional requirements (EU, US, Asia-Pacific); and (3) prepare for potential market expansion of Pfizer's approved drugs, which may require localized support products. The $4.4 billion impairment charge indicates Pfizer is aggressively managing risk, suggesting the company will prioritize regulatory compliance in remaining programs. Cross-border sellers should align product certifications and documentation with Pfizer's therapeutic priorities to ensure market access as the company accelerates phase three programs.",[63,68,72,76,80,85,90,95,101,106,110,115,120,125,129,132,136,140,143,148,153,156,159,163,167,170,175,179,184,189,193,197,201,206,210,214,218,222,227],{"id":64,"title":65,"source":66,"logo":26,"time":67},348654,"Pfizer beats profit estimates on strong drug demand but expects future revenue woes","https://www.theglobeandmail.com/investing/article-pfizer-beats-profit-estimates-on-strong-drug-demand-but-expects-future/","20小時前",{"id":69,"title":70,"source":71,"logo":5,"time":67},349787,"PFIZER ($PFE) Releases Q4 2025 Earnings","https://www.quiverquant.com/news/PFIZER+%28%24PFE%29+Releases+Q4+2025+Earnings",{"id":73,"title":74,"source":75,"logo":16,"time":67},348655,"Pfizer stock falls after solid earnings. What’s troubling Wall Street?","https://www.msn.com/en-us/money/topstocks/pfizer-stock-falls-after-solid-earnings-what-s-troubling-wall-street/ar-AA1Vzrur?ocid=finance-verthp-feeds",{"id":77,"title":78,"source":79,"logo":5,"time":67},349788,"(PFE) Pfizer Expects 2026 Adjusted EPS Range $2.80 to $3, vs. FactSet Est of $2.97","https://www.marketscreener.com/news/pfe-pfizer-expects-2026-adjusted-eps-range-2-80-to-3-vs-factset-est-of-2-97-ce7e5bd2d08ef523",{"id":81,"title":82,"source":83,"logo":35,"time":84},351109,"Pfizer Delivers Solid 2025 Results, Reaffirms 2026 Outlook","https://news.alphastreet.com/pfizer-delivers-solid-2025-results-reaffirms-2026-outlook/","13小時前",{"id":86,"title":87,"source":88,"logo":5,"time":89},349786,"Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates","https://finance.yahoo.com/news/pfizer-pfe-q4-earnings-revenues-125502270.html","19小時前",{"id":91,"title":92,"source":93,"logo":22,"time":94},351902,"Pfizer (PFE) Margin Improvement To 15.6% Challenges Bearish Earnings Narratives","https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/pfizer-pfe-margin-improvement-to-156-challenges-bearish-earn","5小時前",{"id":96,"title":97,"source":98,"logo":99,"time":100},348670,"Pfizer (PFE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates","https://finance.yahoo.com/news/pfizer-pfe-q4-earnings-taking-143003832.html","https://s.yimg.com/ny/api/res/1.2/AVdgrwZgS3kzhpvNmlvreA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQyNw--/https://media.zenfs.com/en/zacks.com/f541c90e0d995722d10914cb76a7c653","18小時前",{"id":102,"title":103,"source":104,"logo":24,"time":105},351905,"Pfizer shares drop on quarterly loss","https://www.themountainpress.com/roane/news/national/pfizer-shares-drop-on-quarterly-loss/article_5c725a53-f858-5b71-94d3-c2dec0f23fcc.html","16小時前",{"id":107,"title":103,"source":108,"logo":29,"time":109},350099,"https://www.msn.com/en-us/money/companies/pfizer-shares-drop-on-quarterly-loss/ar-AA1VAiJX","15小時前",{"id":111,"title":112,"source":113,"logo":33,"time":114},348902,"Pfizer Fourth-Quarter Earnings Unexpectedly Rise; COVID-19 Product Sales Plunge","https://news.futunn.com/en/post/68363864/pfizer-fourth-quarter-earnings-unexpectedly-rise-covid-19-product-sales","12小時前",{"id":116,"title":117,"source":118,"logo":5,"time":119},348903,"Pfizer Stock Falls After Solid Earnings. What’s Troubling Wall Street.","https://www.barrons.com/articles/pfizer-earnings-stock-price-cbedad25?gaa_at=eafs&gaa_n=AWEtsqfuiXYPUPb5vYhmQUImwGc6DVHry-W1dvCtXW5eZF0gioM80p75Xtz2&gaa_ts=6982589c&gaa_sig=2NeA-OZMdP3CQjrnqc0v-fNajGAxu6JBSmd41dWJQ-NOpXDyuEkU4sqm_C7AJ0kznoHBZOf2EKLGRtvKN-4cyA%3D%3D","14小時前",{"id":121,"title":122,"source":123,"logo":5,"time":124},348669,"Pfizer (PFE) Q4 2025 Earnings Call Transcript","https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/37387029/pfizer-pfe-q4-2025-earnings-call-transcript/","17小時前",{"id":126,"title":127,"source":128,"logo":12,"time":89},348901,"Pfizer beats earnings estimates as demand for older drugs offsets COVID slump","https://wkzo.com/2026/02/03/pfizer-beats-earnings-estimates-as-demand-for-older-drugs-offsets-covid-slump/",{"id":130,"title":103,"source":131,"logo":19,"time":105},348667,"https://www.elkharttruth.com/news/national/pfizer-shares-drop-on-quarterly-loss/article_e6c97248-392e-5cab-ae50-e03800861846.html",{"id":133,"title":134,"source":135,"logo":21,"time":105},348668,"Pfizer Projects Revenue Dip in 2026 as Patent Losses Weigh","https://www.tradingview.com/news/gurufocus:9af535de1094b:0-pfizer-projects-revenue-dip-in-2026-as-patent-losses-weigh/",{"id":137,"title":138,"source":139,"logo":25,"time":109},351998,"Why Pfizer shares are under pressure despite a Q4 earnings beat","https://www.msn.com/en-us/money/topstocks/why-pfizer-shares-are-under-pressure-despite-a-q4-earnings-beat/vi-AA1VAvoP?ocid=finance-verthp-feeds",{"id":141,"title":103,"source":142,"logo":10,"time":105},348666,"https://www.indianagazette.com/the_wire/pfizer-shares-drop-on-quarterly-loss/article_4400634e-83a2-5e8a-9095-e1d0d4e83cb0.html",{"id":144,"title":145,"source":146,"logo":5,"time":147},351997,"Pfizer Q4 Earnings Call Highlights","https://finance.yahoo.com/news/pfizer-q4-earnings-call-highlights-060805182.html","2小時前",{"id":149,"title":150,"source":151,"logo":152,"time":109},348663,"Why Pfizer Stock Dropped Today","https://finance.yahoo.com/news/why-pfizer-stock-dropped-today-163657152.html","https://s.yimg.com/ny/api/res/1.2/a2lRsj73GDf2I0dxZ.o8cg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQzMg--/https://media.zenfs.com/en/motleyfool.com/efd735c487b66c91b0b5ffec5db2f7dc",{"id":154,"title":150,"source":155,"logo":27,"time":105},348664,"https://www.fool.com/investing/2026/02/03/why-pfizer-stock-dropped-today/",{"id":157,"title":103,"source":158,"logo":11,"time":105},351999,"https://www.swiowanewssource.com/news/nation/article_a03cf3bb-8297-513a-a6a5-d2f31f4a6298.html",{"id":160,"title":161,"source":162,"logo":14,"time":109},348661,"Pfizer pharmaceutical company earned less in 2025 than last year","https://www.wjournalpr.com/business/pfizer-pharmaceutical-company-earned-less-in-2025-than-last-year/article_7d38023b-882c-4a35-af5e-cfda5cddc6b0.html",{"id":164,"title":165,"source":166,"logo":15,"time":109},348662,"Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever (NYSE:PFE)","https://seekingalpha.com/article/4865357-pfizer-q4-earnings-review-this-classic-value-trap-remains-as-tempting-as-ever",{"id":168,"title":150,"source":169,"logo":5,"time":109},349792,"https://www.theglobeandmail.com/investing/markets/stocks/PFE/pressreleases/37386819/why-pfizer-stock-dropped-today/",{"id":171,"title":172,"source":173,"logo":5,"time":174},350903,"Pfizer Earnings Call: Pipeline Strength Amid COVID Reset","https://www.tipranks.com/news/company-announcements/pfizer-earnings-call-pipeline-strength-amid-covid-reset","8小時前",{"id":176,"title":177,"source":178,"logo":5,"time":109},349793,"Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data","https://finance.yahoo.com/news/pfizer-stock-slides-despite-q4-163200430.html",{"id":180,"title":181,"source":182,"logo":20,"time":183},350904,"Pfizer Reports 9 Percent Increase in Q4 Oncology Revenue as Ibrance Patent Cliff Looms","https://www.precisionmedicineonline.com/precision-oncology/pfizer-reports-9-percent-increase-q4-oncology-revenue-ibrance-patent-cliff-looms","7小時前",{"id":185,"title":186,"source":187,"logo":23,"time":188},349790,"Pfizer Earnings: Seagen Impairment and Metsera Tolerability Data Incrementally Negative","https://www.morningstar.com/stocks/pfizer-earnings-seagen-impairment-metsera-tolerability-data-incrementally-negative","11小時前",{"id":190,"title":191,"source":192,"logo":28,"time":119},349791,"Pfizer shares slump 3.60% on fourth quarter loss, lower 2026 outlook","https://www.livemint.com/market/stock-market-news/pfizer-shares-slump-3-60-on-fourth-quarter-loss-lower-2026-outlook-11770137893646.html",{"id":194,"title":195,"source":196,"logo":30,"time":67},351177,"Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand","https://www.wsj.com/business/earnings/pfizer-sales-fall-on-continued-lower-covid-19-drug-demand-02fee757?gaa_at=eafs&gaa_n=AWEtsqdaTB1UQt5juxprGGq5Ssx6HlWeTtsg2SZdb-KkAU9A_Sxhs6FEmnLM&gaa_ts=6982ca2e&gaa_sig=L1iW7ZR-hRlec2GVagFGvYXvcTc-38-PF-HjkB62QmbBTEVd6mK4y-5yo3NrI_FA4Mux_fFOZXyhN4V0_D4I0A%3D%3D",{"id":198,"title":199,"source":200,"logo":17,"time":114},350905,"Pfizer posts fourth-quarter beat, but takes $4.4B write-down","https://firstwordpharma.com/story/7091053",{"id":202,"title":203,"source":204,"logo":5,"time":205},350906,"Pfizer beats sales estimates on demand for older drugs","https://sg.finance.yahoo.com/news/pfizer-beats-sales-estimates-demand-042731588.html","1天前",{"id":207,"title":208,"source":209,"logo":5,"time":119},348658,"Pfizer Inc (NYSE:PFE) Shock Echoes Russell 1000 index Watchers Track Next Moves","https://kalkinemedia.com/us/stocks/healthcare/pfizer-inc-nysepfe-shock-echoes-russell-1000-index-watchers-track-next-moves",{"id":211,"title":212,"source":213,"logo":32,"time":119},348659,"Pfizer sets sights on R&D strategy amid modest FY25 results","https://www.pharmaceutical-technology.com/news/pfizer-fy25-results-future-directions-obesity-ai/",{"id":215,"title":216,"source":217,"logo":18,"time":84},348656,"Pfizer: Messy Q4 Earnings Mask An Improving Business (NYSE:PFE)","https://seekingalpha.com/article/4865425-pfizer-messy-q4-earnings-mask-an-improving-business",{"id":219,"title":220,"source":221,"logo":34,"time":109},348854,"Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges","https://www.fiercebiotech.com/biotech/pfizer-ceo-promises-pipeline-pruning-finished-after-6-more-early-stage-culls",{"id":223,"title":224,"source":225,"logo":31,"time":226},349789,"Pfizer Shares Slide After Mixed Earnings And Drug Data","https://evrimagaci.org/gpt/pfizer-shares-slide-after-mixed-earnings-and-drug-data-526713","9小時前",{"id":228,"title":229,"source":230,"logo":13,"time":84},348657,"Pfizer reports quarterly loss, affirms 2026 targets","https://www.thestandard.com.hk/market/article/323526/Pfizer-reports-quarterly-loss-affirms-2026-targets","#70c9cbff","#70c9cb4d",1770211881555]